Novo Fires Back at Lilly's Foundayo With Competing Efficacy Data

Eli Lilly’s oral obesity pill Foundayo got FDA approval on April 1. Novo Nordisk published a competing efficacy analysis the next morning.

Novo’s analysis published at 11:31 AM EDT on April 2, within hours of Lilly’s approval and before any prescriber had written a single Foundayo script.

Novo’s data claims its own oral GLP-1 drug outperforms Foundayo on weight loss. The catch: there’s no head-to-head trial. Novo is comparing its drug against Lilly’s using data from separate studies — different patient populations, different designs. Statisticians and formulary committees have a word for that kind of analysis: unreliable.

Novo’s Ozempic and Wegovy, plus Lilly’s Mounjaro and Zepbound, already dominate the injectable GLP-1 market. Pills remove the needle barrier and open the market to patients who won’t self-inject, a population that could dwarf what either company has already captured.

Novo didn’t wait for Lilly to finish celebrating. Its analysis landed within 24 hours of FDA approval. Whether it moves payers is a different question: without a randomized head-to-head, doctors are choosing sides based on incompatible data.

Until a head-to-head trial reads out, payers and prescribers are choosing sides on data that can’t be directly compared.

Sarah Chen